Advicenne Company Description

Advicenne S.A., a specialty pharmaceutical company, develops, commercializes, and markets treatments for rare renal diseases.

Its main drug candidate is Sibnayal, which has completed phase III clinical trial for the treatment of distal renal tubular acidosis, as well as cystinuria.

The company also distributes Likozam, a formulation of clobazam for the treatment of short-term symptomatic of severe, disabling, or condition-causing anxiety unacceptable distress; and Levidcen, a galenic form of levetiracetam for the treatment of epileptic seizures.

Advicenne S.A. was incorporated in 2007 and is headquartered in Paris, France.

Advicenne S.A.

Country	France
Founded	2007
Industry	Biotechnology
Sector	Healthcare
Employees	21
CEO	Didier Laurens

Contact Details

Address: 3ème étage 262 Paris, 75008 France
Phone	33 1 85 73 36 20
Website	advicenne.com

Stock Details

Ticker Symbol	ALDVI
Exchange	Euronext Paris
Fiscal Year	January - December
Reporting Currency	EUR
ISIN Number	FR0013296746
SIC Code	2834

Key Executives

Name	Position
Laurent Cassedanne	Deputy Chief Executive Officer, Deputy GM and Head Pharmacist and Director
Didier Laurens	Chief Executive Officer, MD, General Director and Director
Isabelle Kervella	Chief Financial Officer
Dr. André Ulmann M.D., Ph.D.	Chief Medical Officer and Non-Voting Director
Hege Hellstrom	Chief Commercial Officer
Robbie McCarthy	General Manager of Advicenne Inc.